It is, therefore, reasonable to speculate that RASGRF2-associated immune genes or leukocyte infiltration patterns may provide similar prognostic value in predicting STAD response to immunotherapeutic interventions. Here, RASGRF2 is linked to gastric adenocarcinoma.